MX2019015286A - Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias. - Google Patents

Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias.

Info

Publication number
MX2019015286A
MX2019015286A MX2019015286A MX2019015286A MX2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A MX 2019015286 A MX2019015286 A MX 2019015286A
Authority
MX
Mexico
Prior art keywords
syn
constructs
alpha
peptide immunogen
synucleinopathies
Prior art date
Application number
MX2019015286A
Other languages
English (en)
Spanish (es)
Inventor
Chang Yi Wang
Original Assignee
United Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Neuroscience filed Critical United Neuroscience
Publication of MX2019015286A publication Critical patent/MX2019015286A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
MX2019015286A 2017-06-16 2018-06-15 Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias. MX2019015286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521287P 2017-06-16 2017-06-16
PCT/US2018/037938 WO2018232369A1 (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
MX2019015286A true MX2019015286A (es) 2020-08-17

Family

ID=64659951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015286A MX2019015286A (es) 2017-06-16 2018-06-15 Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias.

Country Status (10)

Country Link
US (1) US20210138049A1 (OSRAM)
EP (1) EP3638298A4 (OSRAM)
JP (3) JP2021508672A (OSRAM)
KR (2) KR20240150813A (OSRAM)
AU (2) AU2018283510B8 (OSRAM)
BR (1) BR112019026707A2 (OSRAM)
CA (1) CA3067231A1 (OSRAM)
MX (1) MX2019015286A (OSRAM)
SG (1) SG11201912195TA (OSRAM)
WO (1) WO2018232369A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
SG11202003624SA (en) 2017-10-27 2020-05-28 United Neuroscience Tau peptide immunogen constructs
SG11202107042WA (en) * 2018-12-28 2021-07-29 United Biomedical Inc Peptide immunogens targeting interleukin 6 (il-6) and formulations thereof for immunotherapy of diseases impacted by il-6 dysregulation
AU2021276401A1 (en) 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
JP2023536497A (ja) * 2020-08-04 2023-08-25 エイシー イミューン ソシエテ アノニム 免疫原性化合物
CN116783211A (zh) * 2020-09-17 2023-09-19 普罗塞纳生物科学有限公司 治疗突触核蛋白病之α-突触核蛋白疫苗
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
US20240270801A1 (en) * 2021-06-18 2024-08-15 Sumitomo Pharma Co., Ltd. Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide
EP4395894A4 (en) * 2021-09-01 2025-08-06 Vaxxinity Inc METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES
MX2024010450A (es) 2022-02-28 2024-09-18 Tridem Bioscience Gmbh & Co Kg Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US20120142902A1 (en) * 2007-02-23 2012-06-07 The Regents Of The University Of California Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
PT2370466E (pt) * 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
WO2013173827A2 (en) * 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
WO2014031697A2 (en) * 2012-08-21 2014-02-27 The Institute Of Molecular Medicine COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US20170184612A1 (en) * 2014-04-09 2017-06-29 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
US10155030B2 (en) * 2014-05-23 2018-12-18 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease

Also Published As

Publication number Publication date
BR112019026707A2 (pt) 2020-06-30
JP7732676B2 (ja) 2025-09-02
RU2020101121A3 (OSRAM) 2021-10-15
JP2025090637A (ja) 2025-06-17
EP3638298A4 (en) 2021-05-05
EP3638298A1 (en) 2020-04-22
AU2018283510B8 (en) 2025-09-18
KR20200054938A (ko) 2020-05-20
AU2018283510B2 (en) 2025-06-26
AU2018283510A1 (en) 2020-01-16
KR20240150813A (ko) 2024-10-16
JP2023082018A (ja) 2023-06-13
US20210138049A1 (en) 2021-05-13
JP2021508672A (ja) 2021-03-11
WO2018232369A1 (en) 2018-12-20
SG11201912195TA (en) 2020-01-30
AU2025238083A1 (en) 2025-10-23
CA3067231A1 (en) 2018-12-20
RU2020101121A (ru) 2021-07-16

Similar Documents

Publication Publication Date Title
MX2019015286A (es) Inmunogenos peptidicos del extremo c-terminal de proteinas alfa-sinucleinas y formulaciones de las mismas para el tratamiento de sinucleinopatias.
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
RU2015122368A (ru) Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
SG10201809779RA (en) Site-specific antibody-drug conjugation through glycoengineering
CY1110051T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii
EA200900795A1 (ru) Вакцина
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
FI3452507T3 (fi) Tau-immuunihoito
ATE439375T1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
BR112017009177A2 (pt) vacinas terapêuticas contra hpv16
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
RU2015154795A (ru) Иммуногенная композиция, ее включающая вакцина, набор для приготовления вышеуказанной композиции и способ лечения заболеваний, связанных с патологией секреции гастрина
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
HRP20220064T1 (hr) Zglobno modificirani fragmenti protutijela i postupci za pripravu
EA201690056A8 (ru) ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
NZ760008A (en) Uti fusion proteins
EA201591108A1 (ru) Слитый гормон роста человека и альбумин, составы и их применения
WO2013171661A3 (en) Adjuvant formulations and methods
MX2021007906A (es) Nmunógenos peptídicos dirigidos a la interleucina 6 (il-6) y sus formulaciones para la inmunoterapia de enfermedades afectadas por la desregulación de la il-6.
AU2018347511A8 (en) Periodontitis vaccine and related compositions and method of use
WO2012050893A3 (en) Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein